含有皮佩拉的先进抑制剂向与肠道毒性相关的微生物β-glucuronidases
Amanda L Graboski1, Joshua B Simpson2, Samuel J Pellock2
1Department of Pharmacology, University of North Carolina Chapel Hill North Carolina USA.
RSC chemical biology
|August 30, 2024
概括
研究人员开发了UNC10206581,这是肠道细菌β-葡萄糖酶 (GUS) 酶的强有力的抑制剂. 这种化合物有效地减少了微生物介导的药物毒性和同源性失调,而不会损害有益的牛GUS.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 肠道细菌β-葡萄糖酶 (GUS) 酶重新激活药物和毒素,影响人类的平衡,并引起副作用.
- 特定的GUS酶,FMN结合和循环1是这种重新激活过程的关键驱动因素.
研究的目的:
- 发现和描述肠道微生物GUS酶的选择性抑制剂.
- 了解用于开发强效和安全的抑制剂的结构-活性关系.
主要方法:
- 合成和测试含有皮佩拉的新型GUS抑制剂.
- 酶动力学,共同晶体结构,以及使用纯化的GUS酶进行体外测试.
- 在微生物培养和人类便样本中使用元基因组和元蛋白组分析进行评估.
主要成果:
- 确定了GUS抑制的关键结构特征 (piperazine放置,核性,环基部分).
- 开发了UNC10206581,它是人类肠道微生物FMN结合和循环1GUS的强有力的抑制剂.
- UNC10206581显示选择性 (没有牛GUS抑制) 和没有毒性在相关剂量.
- 在复杂的微生物系统中证明了UNC10206581的有效性.
结论:
- UNC10206581是缓解药物毒性和肠道微生物引起的恒温不平衡的有前途的治疗.
- 基于结构的设计产生了对有害细菌GUS活动的选择性和强有力的抑制剂.
- 进一步开发有可能治疗与肠道微生物组失调相关的疾病.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Phase II Reactions: Glucuronidation
319
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
319
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145


